331 related articles for article (PubMed ID: 11347142)
1. [Fenofibrate].
Yamashita T; Nakamura H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
[No Abstract] [Full Text] [Related]
2. [Gemfibrozil: new aspects in clinical use].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():625-30. PubMed ID: 11347143
[No Abstract] [Full Text] [Related]
3. [Overviews of fibrate].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
[No Abstract] [Full Text] [Related]
4. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Dobordzhginidze LM
Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
[No Abstract] [Full Text] [Related]
5. [Helsinki Heart Study].
Sekiya M; Ishibashi S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
[No Abstract] [Full Text] [Related]
6. [Pleiotrophic effect of anti-hyperlipemic agents].
Morishita R
Nihon Naika Gakkai Zasshi; 2001 Oct; 90(10):2017-22. PubMed ID: 11769493
[No Abstract] [Full Text] [Related]
7. [Treatment of high blood cholesterol in patients with coronary heart disease].
Nagai Y; Yamashita S
Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049
[No Abstract] [Full Text] [Related]
8. Correction to the FIELD study report.
Keech A; Simes J; Barter P; Best J; Scott R; Taskinen MR;
Lancet; 2006 Oct; 368(9545):1415. PubMed ID: 17055933
[No Abstract] [Full Text] [Related]
9. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Samineni D; Fichtenbaum CJ
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
[TBL] [Abstract][Full Text] [Related]
10. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.
Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Trends Pharmacol Sci; 2003 Oct; 24(10):530-4. PubMed ID: 14559405
[No Abstract] [Full Text] [Related]
11. [KLAS [Kanazawa Lipid Assessment Survey]].
Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
[No Abstract] [Full Text] [Related]
12. Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model.
Rizvi F; Puri A; Bhatia G; Khanna AK; Wulff EM; Rastogi AK; Chander R
Biochem Biophys Res Commun; 2003 May; 305(2):215-22. PubMed ID: 12745061
[TBL] [Abstract][Full Text] [Related]
13. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Chan NN; Chow FC
Lancet; 2001 Nov; 358(9295):1811; author reply 1811-2. PubMed ID: 11734263
[No Abstract] [Full Text] [Related]
14. [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].
Higashikata T
Nihon Rinsho; 2004 Mar; 62 Suppl 3():628-36. PubMed ID: 15171447
[No Abstract] [Full Text] [Related]
15. [Other antihyperlipidemic drugs with novel mechanism].
Yamashita S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():681-9. PubMed ID: 11347153
[No Abstract] [Full Text] [Related]
16. [Lipid determination in current medical practice].
Bakir R; Chanu B; Rouffy J
Ann Dermatol Venereol; 1986; 113(9):855-9. PubMed ID: 3827091
[No Abstract] [Full Text] [Related]
17. Implications of 4S evidence on baseline lipid levels.
Durrington PN
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
[No Abstract] [Full Text] [Related]
18. Hyperlipidemia in atherosclerosis. Dietary and drug treatment.
Kuo PT
Med Clin North Am; 1970 May; 54(3):657-69. PubMed ID: 5429542
[No Abstract] [Full Text] [Related]
19. Fenofibrate and diabetic retinopathy.
Fagan XJ; Chong EW
Clin Exp Ophthalmol; 2015; 43(4):297-9. PubMed ID: 26099043
[No Abstract] [Full Text] [Related]
20. Fibrates and homocysteine.
Young IS; Woodside JV
Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
